NF-kB and Fibrosis

### **NF-κB and Fibrosis: A Detailed Overview**

Nuclear Factor-kappa B (NF-κB) is a transcription factor that plays a pivotal role in inflammation, immunity, cell survival, and apoptosis. Dysregulation of NF-κB signaling is a key driver of chronic inflammatory diseases, cancer, and fibrosis. Fibrosis is a pathological process marked by excessive extracellular matrix (ECM) deposition, tissue scarring, and organ dysfunction, and NF-κB is central to its initiation and progression.

---

### **Mechanisms of NF-κB in Fibrosis**

#### **1. NF-κB Activation in Fibrosis**

NF-κB becomes activated in response to various stimuli, such as:

• **Pro-inflammatory cytokines**: Tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β).
• **Pathogen-associated molecular patterns (PAMPs)**: Lipopolysaccharides (LPS) from microbes.
• **Damage-associated molecular patterns (DAMPs)**: Reactive oxygen species (ROS), cellular debris.
• **Mechanical stress**: Tissue injury or organ damage.

NF-κB activation occurs through two major pathways:

• **Canonical Pathway**: Involves the degradation of the inhibitor of κB (IκB), allowing NF-κB dimers (e.g., p65/p50) to translocate into the nucleus and regulate gene transcription.
• **Non-Canonical Pathway**: Involves processing of p100 into p52, forming RelB/p52 complexes that regulate a distinct set of genes.

---

#### **2. Inflammation as a Driver of Fibrosis**

• NF-κB is a master regulator of inflammation and induces the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β) and chemokines (e.g., MCP-1).
• Chronic inflammation leads to the recruitment and activation of immune cells, such as macrophages, neutrophils, and lymphocytes.
• These immune cells release additional cytokines, perpetuating the inflammatory cycle and driving the activation of fibrogenic cells like fibroblasts and myofibroblasts.

---

#### **3. Activation of Fibrogenic Cells**

• **Fibroblasts and Myofibroblasts**: NF-κB promotes the activation of these cells, which are the primary producers of ECM components like collagen and fibronectin.
• **Hepatic Stellate Cells (HSCs)**: In liver fibrosis, NF-κB drives the activation of HSCs, leading to excessive ECM deposition.
• **TGF-β Upregulation**: NF-κB increases the expression of transforming growth factor-beta (TGF-β), a master regulator of fibrosis. TGF-β further activates fibroblasts and myofibroblasts, amplifying ECM production.

---

#### **4. Crosstalk with Other Fibrotic Pathways**

NF-κB interacts with other signaling pathways to amplify fibrotic processes:

• **TGF-β/Smad Pathway**: NF-κB enhances TGF-β signaling, which is central to fibrosis.
• **Wnt/β-Catenin Pathway**: NF-κB interacts with Wnt signaling to promote fibroblast activation.
• **Oxidative Stress**: NF-κB promotes the production of ROS, which further activates fibrogenic pathways.

---

#### **5. Inhibition of ECM Degradation**

• NF-κB upregulates **tissue inhibitors of metalloproteinases (TIMPs)**, which inhibit matrix metalloproteinases (MMPs). This reduces ECM degradation and promotes ECM accumulation, leading to tissue scarring.

---

### **NF-κB in Specific Fibrotic Diseases**

#### **1. Liver Fibrosis**

• Chronic liver diseases such as hepatitis B/C, alcoholic liver disease, and non-alcoholic steatohepatitis (NASH) activate NF-κB in Kupffer cells, hepatocytes, and hepatic stellate cells.
• NF-κB drives the production of TGF-β and pro-inflammatory cytokines, leading to collagen deposition and fibrosis progression.

#### **2. Pulmonary Fibrosis**

• In idiopathic pulmonary fibrosis (IPF), NF-κB is activated in alveolar macrophages, epithelial cells, and fibroblasts.
• This promotes inflammation, fibroblast activation, and ECM production, contributing to lung scarring.

#### **3. Renal Fibrosis**

• In chronic kidney disease (CKD), NF-κB activation in tubular epithelial cells and interstitial fibroblasts drives inflammation, fibroblast activation, and ECM deposition.

#### **4. Cardiac Fibrosis**

• NF-κB contributes to myocardial fibrosis in response to ischemia, hypertension, or pressure overload.
• It promotes fibroblast activation, TGF-β signaling, and collagen deposition in the heart.

---

### **Key Molecular Players in NF-κB-Mediated Fibrosis**

| **Molecule** | **Role in Fibrosis** |

|------------------------|-------------------------------------------------------------------------------------|

| **TGF-β** | Master regulator of fibrosis; upregulated by NF-κB. |

| **IL-1β, TNF-α** | Pro-inflammatory cytokines driving fibrogenesis. |

| **PDGF** | Stimulates fibroblast proliferation and ECM production. |

| **MCP-1 (CCL2)** | Recruits monocytes/macrophages, amplifying inflammation and fibrosis. |

| **TIMP-1, TIMP-2** | Inhibit ECM degradation, promoting ECM accumulation. |

| **ROS** | Enhances NF-κB activation and drives oxidative stress-related fibrogenesis. |

---

### **Therapeutic Implications: Targeting NF-κB in Fibrosis**

Given its central role in fibrosis, NF-κB is an attractive therapeutic target. Strategies to modulate NF-κB activity include:

#### **1. NF-κB Inhibitors**

• **IKK Inhibitors**: Block IκB kinase activity, preventing IκB degradation and NF-κB activation.
• Example: **BAY 11-7082** (experimental inhibitor).
• **Proteasome Inhibitors**: Prevent degradation of IκB, retaining NF-κB in its inactive state.
• Example: **Bortezomib** (FDA-approved for multiple myeloma, under investigation for fibrosis).

#### **2. Anti-Inflammatory Therapies**

• **TNF-α Inhibitors**: Blockade of upstream cytokines like TNF-α (e.g., **infliximab**) can reduce NF-κB activation.
• **IL-1β Inhibitors**: Drugs like **anakinra** target IL-1β, reducing inflammation.

#### **3. Antioxidants**

• Agents like **N-acetylcysteine (NAC)** reduce oxidative stress, indirectly suppressing NF-κB activation.

#### **4. TGF-β Inhibition**

• Targeting TGF-β signaling downstream of NF-κB can attenuate fibrosis.
• Example: **Fresolimumab** (anti-TGF-β monoclonal antibody).

#### **5. Modulation of Gut-Liver Axis**

• In liver fibrosis, strategies to reduce gut-derived PAMPs (e.g., probiotics, antibiotics) can decrease NF-κB activation in Kupffer cells.

---

### **Conclusion**

NF-κB is a central mediator of fibrosis, driving inflammation, fibroblast activation, TGF-β production, and ECM deposition. Its dysregulation contributes to the progression of fibrotic diseases in the liver, lungs, kidneys, and heart. Targeting NF-κB and its downstream pathways offers a promising therapeutic approach to mitigate fibrosis and prevent organ dysfunction in chronic diseases.